KYTX
Kyverna Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$564.05M
P/E Ratio
—
EPS
$-3.64
Beta
2.64
52W High
$13.67
52W Low
$1.78
50-Day MA
$8.25
200-Day MA
$6.46
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc. is an innovative biotechnology company specializing in the development of advanced immunotherapies for autoimmune diseases and serious medical conditions. Utilizing its cutting-edge genetically engineered T-cell technology, the firm aims to enhance the immune system's capabilities, offering targeted solutions for effective disease management. With a strategic focus on cellular therapies, Kyverna is well-positioned within the biopharmaceutical sector, presenting compelling opportunities for institutional investors looking to support transformative treatments and capitalize on growth in the immunotherapy landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-133.72M |
| EBITDA | $-168.03M |
| Operating Margin | 0.00% |
| Return on Equity | -64.70% |
| Return on Assets | -35.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.85 |
| Price-to-Book | 2.31 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | 3341.48 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.45M |
| Float | $35.12M |
| % Insiders | 7.11% |
| % Institutions | 74.35% |
Analyst Ratings
Consensus ($29.60 target)
2
Strong Buy4
BuyData last updated: 4/8/2026